Abstract. Hepatic triacylglycerol (TAG) homeostasis is maintained by carefully regulated balance between its synthesis and disposal. Impairment in this balance causes steatosis. The aims of this study were i) to uncover whether fibrates control TAG concentration through the action of adipose triglyceride lipase (ATGL) and ii) to compare the potency of the effects on ATGL expression and TAG concentration among fenofibrate, bezafibrate, and clofibric acid in the liver of rats. Treatments of rats with the three fibrates induced ATGL and concomitantly decreased hepatic TAG concentration. The upregulation of ATGL was likely mediated through the activation of peroxisome proliferator-activated receptor a. Fibrates also expanded capacity of fatty acid b-oxidation. Importantly, three fibric acids (fenofibric, bezafibric, and clofibric acids) that are active metabolites formed in the liver exhibited almost the same potency to elevate ATGL expression in vivo, despite the fact that there were considerable differences in this regard among fenofibrate, bezafibrate, and clofibric acid when compared on the basis of their dosage. These results suggest that ATGL represents a potential therapeutic target for ameliorating hepatic steatosis and that fibric acids are promising agents to ameliorate and/or protect against hepatic steatosis.
Introduction
Fibrates are well known as a class of drugs used to treat dyslipidemia, in particular hypertriglyceridemia. The primary clinical outcomes are decreased plasma triacylglycerol (TAG), increased low-density lipoprotein size, increased high-density lipoprotein synthesis, and increased reverse cholesterol transport, thus reducing the risk of cardiovascular disease (1 -5) . Moreover, there is increasing evidence with regard to the amelioration of insulin sensitivity and vascular and systemic inflammation by fibrates (1, 3, 6) . In hepatocytes, excessive accumulation of TAG is the common denominator of a wide range of pathophysiological entities known as hepatic steatosis or nonalcoholic fatty liver disease (NAFLD). Tight regulation between TAG synthesis, hydrolysis, secretion, and fatty acid oxidation is required to prevent TAG accumulation in the liver. Therefore, understanding the pathway that regulates hepatic TAG metabolism in the liver is critical for the development of therapies to ameliorate pathophysiological conditions associated with excessive hepatic TAG accumulation, such as hepatic steatosis and NAFLD. However, it remains yet to be established whether fibrates ameliorate NAFLD (7, 8) . This may be due to the fact that the biochemical mechanism behind the effects of fibrates on the regulation and physiological function of adipose triglyceride lipase (ATGL) in TAG metabolism is not fully understood in the liver.
Catabolism of TAG is believed to be initiated by the action of ATGL, which is known to catalyze the initial step in lipolysis by hydrolyzing TAG into diacylglycerol and free fatty acid (9) . Consequently, it is most likely that functional deficiency of ATGL results in TAG accumulation in essentially all tissues and cells. ATGL is expressed in most tissues with the highest expression in adipose tissues but very low expression in the liver (9) . Subsequent studies have identified ATGL as a major functional lipase in adipose tissue (10) , whereas its role in the liver has been poorly understood. However, there is evidence demonstrating that ATGL ablation leads to pronounced hepatic steatosis, whereas increasing ATGL production in the liver reduces hepatic steatosis in rodents (11 -14) . These findings suggest that ATGL plays a pivotal role in TAG metabolism in the liver and that ATGL represents a pharmacological therapeutic target for NAFLD. In this regard, it is of interest to understand in detail the effects of fibrates on ATGL in the liver. As far as we know, very few studies have been carried out in vivo on whether fibrates cause modification of ATGL function in the liver. There are several kinds of fibrates. Clofibrate (ethyl ester of clofibric acid) is a prototype of fibrates, but has been gradually replaced by more efficient drugs, like fenofibrate (isopropyl ester of fenofibric acid) and bezafibrate (also referred to as bezafibric acid). On the other hand, it is now considered that there are differences in the mode of actions among fibrates (15 -17) . However, fundamental information is lacking about the action of fibrates on hepatic ATGL, despite the fact that these drugs are the most promising agents for the therapy of hepatic steatosis. In this context, the present study aimed i) to uncover whether fibrates regulate TAG concentration through the action of ATGL and ii) to compare the potency of the effects on ATGL expression among fenofibrate, bezafibrate, and clofibric acid in the liver of rats.
Fibrates Reduce Triacylglycerol Content by Upregulating Adipose Triglyceride Lipase in the Liver of Rats

Materials and Methods
Materials
The following reagents were obtained from the indicated commercial sources: bezafibrate, clofibric acid, fenofibrate, phosphatidylcholine (from egg yolk), phosphatidyl-inositol (from soybean), triolein, 4-bromomethyl-6,7-dimethoxycoumarin (BrMDMC), and bovine serum albumin (BSA) (Sigma-Aldrich Co., St. Louis, MO, USA); 18-crown-6-ether (Wako Chemicals, Osaka); anti ATGL (F-7) mouse monoclonal IgG (Santa Cruz Biotechnology, Inc., Dallas, TX, USA); anti mouse IgG HRP-linked antibody (Cell Signaling Technology, Inc., Danvers, MA, USA). Triolein [carboxyl- 14 C] (108.8 mCi/mmol) was purchased from PerkinElmer (Waltham, MA, USA) and then purified by thin-layer chromatography (TLC) on silica gel G plates, which were developed with n-hexane/diethyl ether/acetic acid (80:30:1, by vol.). The regions that corresponded to TAG were scraped-off and transferred to a tube. [ 14 C]TAG was extracted from the silica gel as described previously (18) .
Animals
All animal procedures were approved by Josai University's Institutional Animal Care Committee in accordance with the Guidelines for Proper Conduct of Animal Experiments (Science Council of Japan). Male Wistar rats were obtained from SLC (Hamamatsu). The animals were fed on a standard diet (CE-2; Clea Japan Inc., Tokyo) ad libitum and allowed free access to water. After acclimatization for at least 1 week, rats aged 8 weeks were fed on a diet admixed with fenofibrate, bezafibrate, or clofibric acid. To examine the doseresponse effects, the rats were fed on a diet containing various concentrations of fenofibrate [0%, 0.025%, 0.05%, 0.1%, or 0.2% (w/w)], bezafibrate [0%, 0.025%, 0.05%, 0.1%, or 0.2% (w/w)], or clofibric acid [0%, 0.05%, 0.1%, 0.15%, 0.2%, or 0.3% (w/w)] for 14 days. Food consumption by each rat was measured and the amounts of fibrates taken in by each rat were calculated. In time-course experiments, the rats were fed on a diet containing 0.1% (w/w) fenofibrate, 0.1% (w/w) bezafibrate, or 0.3% (w/w) clofibric acid for 0, 2, 7, or 14 days. Under diethyl ether anesthesia, blood was withdrawn from the inferior vena cava and serum was prepared. The liver was rapidly removed, washed with saline, and weighed. It was then divided into small portions, frozen in liquid nitrogen, and stored at −80°C for biochemical and analytical determinations.
Determination of TAG
Total lipid was extracted from frozen liver tissues by the method of Bligh and Dyer (19) . TAG was separated by TLC on silica gel G plates, which were developed with n-hexane/diethyl ether/acetic acid (80:30:1, by vol.). After visualization by spraying the plates with 0.001% (w/v) primuline in 80% acetone, the regions that corresponded to TAG were scraped-off and transferred to tubes. TAG was extracted from silica gel as described previously (18) . The TAG extract was dried under a flow of nitrogen and re-dissolved in isopropanol-chloroform (9:1, v/v) containing 9% (v/v) Triton X-100 and then assayed for TAG concentration using a commercially available kit (Triglyceride E-Test Wako; Wako Chemicals). TAG in the serum was directly determined using the kit.
Determination of fibric acids
One part of the liver was homogenized in nine volumes of 0.25 M sucrose-1 mM EDTA-10 mM potassium phosphate buffer (pH 7.4) in a Potter glass-Teflon homogenizer. Fibric acids were extracted and analyzed as described previously (20) . In brief, fibric acids were extracted into n-hexane-ethyl acetate (85:15, by vol.) from liver homogenates (10 mg of liver) after acidification with 0.5 M HCl, back-extracted with 0.1 M disodium hydrogen phosphate, and then re-extracted with nhexane-ethyl acetate after acidification with 0.5 M HCl. The obtained fibric acids were derivatized with BrMDMC and 18-crown-6-ether and were separated isocratically on a reversed phase with acetonitrile-water (43:57, v/v) for derivatives of clofibric acid and bezafibric acid and with acetonitrile-water (46:54, v/v) for derivatives of clofibric acid and fenofibric acid by highperformance liquid chromatography with fluorescence detection (excitation at 340 nm and emission at 425 nm).
Quantitation of mRNA
For the determination of mRNA, one portion of the liver was frozen in liquid nitrogen and then stored at −80°C. Total RNA was isolated from the liver tissues using QIAzol reagent and the RNeasy kit (QIAGEN, Hilden, Germany). cDNA was synthesized from 500 ng of total RNA, as described previously (21) . PCR amplification was carried out using SYBR Premix EX Taq (2x, Perfect Real Time; Takara Bio, Inc., Otsu). The amplification and detection were performed with the Applied Biosystems Step One Plus TM real-time PCR system (Life Technologies Corp., Carlsbad, CA, USA). The thermal cycling program was as follows: 10-s denaturation step at 95°C followed by 50 cycles of 5-s denaturation at 95°C, and 34-s annealing at 60°C. Melting curve analysis was performed to confirm the real-time quantitative RT-PCR products. Changes in gene expression were calculated using the comparative threshold cycle (Ct) method. Ct values were first normalized by subtracting the Ct value obtained from b-actin (control). The sequences of primers used in this study are listed in Table 1 .
Western blot analysis
Western blot analyses were performed essentially according to Reid et al. (14) . Briefly, one portion of the liver was homogenized in RIPA lysis buffer [25 mM Tris-HCl (pH 7.6), 150 mM NaCl, 1% NP40, 1% sodium deoxycholate, and 0.1% sodium dodecyl sulfate supplemented with protease inhibitors (aprotinin at 2 mg/ml, bestatin at 13.8 mg/ml, leupeptin at 10 mg/ml, pepstatin at 5 mg/ml and AEBSF at 250 mg/ml)] using a Polytrone RT2100 homogenizer (Kinematica, Luzern, Switzerland) at 4°C, incubated on ice for 30 min, and centrifuged at 10,000 × g for 10 min at 4°C. The supernatants were recentifuged at 10,000 × g for 10 min, and the resulting supernatants were collected for determination of protein concentration using BCA protein assay reagent (Thermo Fisher Scientific, Waltham, MA, USA), with BSA as a standard. Total tissue lysates containing 10 mg of protein were heated at 100°C in 0.063 M Tris-HCl (pH 6.8) containing 5% (v/v) 2-mercaptoethanol, 2% sodium dodecyl sulfate, 6% (v/v) glycerol, and 0.02% bromophenacylblue. The denatured samples underwent sodium dodecyl sulfate/polyacrylamide gel (8%) electrophoresis. Proteins were then transferred onto a polyvinylidene difluoride membrane (Amersham Hybond-P PVDF Transfer membrane; GE Healthcare, Buckinghamshire, England) using a Trans-Blot Semi-Dry Transfer Cell (Bio-Rad Inc., Hercules, CA, USA). Membranes were incubated at room temperature for 30 min with blocking buffer [Tris-buffered saline (pH 7.6) containing 0.1% Tween 20, 5% skim milk, and 1% BSA]. Membranes were incubated with anti-ATGL (F-7) mouse monoclonal IgG. After 12 h of incubation, the membranes were washed 3 times in Tris-buffered saline (pH 7.6) containing 0.1% Tween 20. Membranes were then incubated with a secondary antibody conjugated to horseradish peroxidase (anti-mouse IgG HRP-linked antibody) for 2 h. Membranes were washed three times with Trisbuffered saline (pH 7.6) containing 0.1% Tween 20. Proteins were visualized using the ECL Prime Western Blotting Detection Reagent (GE Healthcare) and detected in a LAS-1000 (GE Healthcare).
Measurement of TAG hydrolase activity
The cytoplasmic fraction was prepared as previously described (12, 22) . About 1 g of the liver was homogenized in 4 vol of homogenate buffer (0.5 M sucrose, 1 mM EDTA, 20 mM Tris-HCl (pH 7.4), 1 mM dithioerythritol, leupeptin at 20 mg/ml, antipain at 2 mg/ml, and pepstatine at 1 mg/ml) using a Dounce homogenizer. The homogenates were centrifuged at 1,000 × g for 10 min. The resulting supernatant was applied to a discontinuous gradient of 0.25 M, 0.5 M (the supernatant of homogenate), and 1.5 M sucrose. The tubes were centrifuged at 100,000 × g in a swinging bucket rotor for 3 h. The 0.5 M sucrose fraction was collected and used as cytoplasmic fraction. TAG hydrolase activity was measured essentially as previously described (12) with some modifications. Substrate was prepared as described previously (23) . Briefly, 2.96 mg (3 mCi) of [ 14 C]triolein (final specifc radio activity, 0.9 mCi/mmol) and 300 mg of phosphatidylcholine/phosphatidylinositol (3:1) were mixed. After drying under nitrogen and then in vacuo, the mixture was emulsified by sonication using an Astrason ultrasonic processor XL2020 (Misonix, Inc., Farmingdale, NY, USA) in 1.5 ml of 0.1 M potassium phosphate buffer (pH 7.0). Then 0.5 ml of 20% (w/v) BSA (defatted) in 0.1 M potassium phosphate buffer (pH 7.0) was added to the emulsion, and the mixture was gently vortexmixed. For each assay, 100 ml substrate solution with 50 ml cytoplasmic fraction and 50 ml buffer (20 mM potassium phosphate, 1 mM EDTA, 1 mM dithioerythritol and 0.02% (w/v) defatted BSA, pH 7.0) were incubated for 60 min at 37°C. The incubation mixture without cytoplasmic fraction was run simultaneously. Each reaction was stopped by adding 6 ml of chloroform/ methanol (1:2, v/v), and then oleic acid (56.4 mg as ethanol solution) and diolein (124.2 mg as ethanol solution) were added as carriers. After mixing, 1.4 ml of 0.1 M HCl was added to the mixture. Lipids were extracted as previously described (19) . The extracts were taken to dryness under a flow of nitrogen, and the dried lipids were dissolved in a known volume of chloroform/ methanol (1:1, v/v). An aliquot of the solution was used to measure total radioactivity in the extract. Another aliquot of the solution was subjected to TLC on silica gel G plates, which were developed with n-hexane/ diethyl ether/acetic acid (80:30:1, by vol.). After visualization by spraying the plate with primuline solution, the regions that corresponded to fatty acid, diacylglycerol, and monoacylglycerol were scraped off and transferred to tubes. These lipids were extracted from silica gel as described previously (18), and the extracts obtained were transferred to vials. After being dried under a flow of nitrogen, the residues obtained were dissolved in scintillator, and radioactivities were counted to calculate the amounts of TAG hydrolyzed. The control value, which was obtained from the incubation without cytoplasmic fraction, was subtracted to give the net TAG hydrolyzed by the cytoplasmic fraction.
Statistical analyses
Data were analyzed by one-way ANOVA followed by Scheffé's multiple range test as a post hoc test. Differences were considered significant at a P-value < 0.05. Linear regression analysis was performed to evaluate the correlation between two variables.
Results
Body weight and daily food intake of the rat were measured throughout the treatment. The body weights of treated rats were similar to that of the control (Fig. 1A) . Daily food intake was not significantly changed by the treatment (Fig. 1B) . On the basis of these data, the amounts of fibrate taken in by each rat were calculated ( Fig. 1: C, D, E ). There were very strong linear correlations between the % of fibrate in the diet and the calculated dose. These results indicated that the dietary concentrations of fenofibrate at 0.025%, 0.05%, 0.1%, and 0.2% (w/w) correspond to, respectively, 15.2 ± 2.7, 34.3 ± 5.0, 67.7 ± 10.4, and 133.4 ± 22.1 mg/kg body weight per day; that those of bezafibrate at 0.025%, 0.05%, 0.1%, and 0.2% (w/w) correspond to, respectively, 17.0 ± 3.2, 34.0 ± 5.3, 66.6 ± 11.7, and 140.6 ± 25.5 mg/kg body weight per day; and that those of clofibric acid at 0.05%, 0.1%, 0.15%, 0.2%, and 0.3% (w/w) correspond to, respectively, 34.1 ± 4.9, 66.4 ± 16.4, 98.8 ± 20.2, 134.5 ± 30.8, and 202.1 ± 40.2 mg/kg body weight per day. Thus, substantially, there was no difference in the calculated dose among the animal groups treated with the three fibrates. These results may allow us to compare the effects of three fibrates on TAG levels in the liver.
Dose-and time-dependent reduction of hepatic TAG by fibrates
Contents of TAG in the liver of rats that were treated with fenofibrate, bezafibrate, and clofibric acid at various doses for 14 days were estimated; the treatments with the three fibrates significantly decreased hepatic contents of TAG in dose-dependent manners ( Fig. 2: A, C, E) . At a dietary concentration of 0.1% (w/w), TAG contents in the liver of rats that were treated with fenofibrate and bezafibrate were 48% and 58%, respectively, of those of the control. Although the treatments of rats with 0.1% (w/w) clofibric acid did not significantly reduce hepatic TAG contents, TAG contents in the liver of rats treated with 0.3% (w/w) clofibric acid were 40% of those of the control. The treatments of rats with 0.1% (w/w) fenofibrate, 0.1% (w/w) bezafibrate, or 0.3% (w/w) clofibric acid reduced hepatic contents of TAG in timedependent manners ( Fig. 2: B, D, F) . The treatments of rats with fenofibrate and bezafibrate significantly decreased serum concentrations of TAG; clofibric acid tended to reduce it, but not significantly (Fig. 3) .
To gain insight into the molecular basis of TAG reduction by fibrates, mRNA levels of key enzymes involved in the metabolism of fatty acids and TAG in the liver of rats that were fed a diet containing 0.1% (w/w) fenofibrate, 0.1% (w/w) bezafibrate, or 0.3% (w/w) clofibric acid for 14 days were estimated ( Table 2 ). The treatments with the fibrates upregulated the expression of Fibrates did not change the mRNA levels for either FATP4, plasma membrane-associated fatty acid binding protein (FABPpm) or ACSL5, except for slight upregulation of ACSL5 expression by fenofibrate. With regard to fatty acid synthesis, the levels of mRNAs encoding fatty acid elongase 6 (Elovl6) and stearoyl-CoA desaturase 1 (SCD1) were elevated by the three fibrates, but that of fatty acid synthease (FAS) was increased by only fenofibrate. As for enzymes involved in glycerolipid synthesis, fenofibrate and bezafibrate slightly augmented mRNA level of glycerol-3-phosphate acyltransferase 4, whereas it was decreased by clofibric acid. Gene expression of DGAT2 was slightly downregulated by the three fibrates; on the other hand, fenofibrate alone increased mRNA level of DGAT1. : Differences in the mean without a common superscript (a, b, or c) are statistically significant (P < 0.05). In the absence of a superscript, the differences in the means are not significant (P > 0.05). : Differences in horizontal means without a common superscript (a, b, c, d) are significant (P < 0.05). In the absence of a superscript, the differences in the means are not significant (P > 0.05).
Upregulation of ATGL by fibrates
Levels of mRNA encoding ATGL in the liver of rats that were treated with fenofibrate, bezafibrate, and clofibric acid at various doses for 14 days were estimated (Fig. 4: A, C, E) . At relatively low doses, fenofibrate, and bezafibrate elevated the mRNA level of ATGL more potently than clofibric acid did. The mRNA level of ATGL rose with an increasing dose of fibrates and almost reached a plateau at 0.1% (w/w) fenofibrate, 0.1% (w/w) bezafibrate, or 0.15% (w/w) fibric acid. When comparing the potency at a dietary concentration of 0.1% (w/w), fenofibrate, bezafibrate, and clofibric acid increased the mRNA level of ATGL by 4.5-, 4.3-, and 1.1-fold, respectively. Moreover, the treatments of rats with the three fibrates increased the level of mRNA encoding ATGL in time-dependent manners (Fig. 4: B,  D, F) . The level of mRNA for CGI-58 in the liver was also increased by the treatments of rats with the three fibrates in dose-and time-dependent manners (Fig. 5) . To estimate the relationship between the level of ATGL mRNA and the concentration of TAG in the liver, linear regression analysis was performed (Fig. 6 ). There was a fairly strong inverse correlation between the mRNA level of ATGL and the content of TAG (r 2 = 0.6808). We next measured TAG hydrolase activity in the cytoplasmic fraction of livers of the rats that were treated with three fibrates, with [ 14 C]triolein as a substrate. The treatment with 0.1% (w/w) fenofibrate and 0.3% (w/w) clofibric acid for 14 days increased TAG hydrolase activity by 1.8-and 1.6-fold, respectively, compared with that of the control, and the treatment with 0.1% (w/w) bezafibrate tended to elevate the activity by 1.4-fold (Fig. 7) . The effects of the three fibrates on the ATGL protein level in the liver were also evaluated by western blot analysis (Fig. 8) . The ATGL protein levels in the liver of rats, which were fed a diet containing one of 0.1% (w/w) fenofibrate, 0.1% (w/w) bezafibrate, and 0.3% (w/w) clofibric acid for 14 days, were 2.7-, 3.8-, and 3.5-fold, respectively, greater than that of the control. : Differences in the mean without a common superscript (a, b, or c) are statistically significant (P < 0.05). In the absence of a superscript, the differences in the means are not significant (P > 0.05).
To understand the possible involvement of peroxisome proliferator-activated receptor a (PPARa) in the induction of ATGL, the relationship between the level of the mRNA encoding acyl-CoA thioesterase 1 (Acot1), a typical PPARa target gene, and that encoding ATGL was examined (Fig. 9) . Upon the treatment of rats with various doses of fenofibrate, bezafibrate, and clofibric acid, the level of the mRNA for Acot1 in the liver rose with increasing dose (Fig. 9A) . Linear regression analysis revealed a strong correlation between the mRNA level of Acot1 and that of ATGL (r 2 = 0.9383) (Fig. 9B) .
Potency of fibric acids to induce ATGL and to reduce TAG in the liver
To estimate the potency of fibric acids to upregulate ATGL and reduce TAG in the liver, hepatic concentrations of fibric acids, active forms of fibrates, in the liver of rats treated with various doses of fibrates for 14 days were measured (Fig. 10A ). There was a large difference in hepatic concentration between clofibric acid and fenofibric acid or bezafibric acid. However, the concentration of clofibric acid in the liver of rats treated with 0.3% (w/w) clofibric acid was almost the same as those of fenofibric acid and bezafibric acid in the livers of rats fed a diet containing 0.1% (w/w) fenofibrate or 0.1% (w/w) bezafibrate. Figure 10B shows the relationship between the concentration of fibric acids and the mRNA level of ATGL in the liver; there was a strong correlation between these two variables (r 2 = 0.9025). Moreover, a fairly good inverse correlation was observed between fibric acid concentration and TAG content in the liver (r 2 = 0.8008) (Fig. 10C) .
Discussion
The present study clearly showed that three fibrates, fenofibrate, bezafibrate, and clofibric acid, reduced the hepatic concentration of TAG in dose-and time-dependent manners, although conflicting results appear in the literature concerning the effects of fenofibrate on hepatic TAG content (11, 24) . In the current study, fenofibrate behaved as the most powerful hepatic TAG suppressor, while clofibric acid was the least potent. The order of potency in decreasing hepatic TAG (fenofibrate ≥ bezafibrate > clofibric acid) did not always agree with the reported manifestation of PPARa activation (25) . To date, the TAG-reducing activity of fibrates has been considered to be mainly mediated by the elevation of peroxisomal and mitochondrial fatty acid degradation. Nevertheless, the detailed mechanism underlying the action of fibrates to reduce hepatic TAG is not fully understood. Hepatic TAG concentration is maintained by a carefully regulated balance of the two predominant metabolic pathways of synthesis and disposal in the liver. Namely, hepatic TAG content could be controlled by i) de novo fatty acid synthesis, ii) delivery of fatty acids from extra-hepatic sources, iii) TAG synthesis, iv) fatty acid b-oxidation, and v) secretion of very-low-density lipoprotein (VLDL). To deal with these possibilities, we measured the expression of genes encoding enzymes and proteins for lipid degradation, fatty acid translocation/trafficking, and lipogenesis. The expression of genes for enzymes involved in oxidation and utilization of fatty acids, CPT1a, MCAD, LCAD, Acox1, and ACSL1, was significantly upregulated by all the three fibrates. These results strongly suggest the increased degradation of fatty acids in hepatocytes, which is generally considered to be the cause of the reduction of hepatic TAG by fibrates (26, 27) . As for the contributions of mitochondrial and peroxisomal b-oxidation to total fatty acid boxidation in the liver, Mannaerts et al. (28) has estimated the contribution of peroxisomal b-oxidation to total fatty acid oxidation to be less than 10% in the living hepatocytes from both control and clofibrate-treated rats, despite the fact that activity of peroxisomal b-oxidation in liver homogenates is strikingly increased by the treatment of rats with clofibrate. The same authors demonstrated that the activity of mitochondrial b-oxidation is increased several fold in both the liver homogenates and the living hepatocytes by the treatment of rats with clofibrate. Our current results that fibrates upregulated the expression of the gene for CPT1a are in good agreement with the results of Mannaerts et al. (28) because CPT1a is a critical rate-determining regulator of mitochondrial b-oxidation in the liver (29) . A previous study demonstrated that a moderate upregulation of CPT1a is Fig. 9 . Upregulation of the expression of ATGL gene and Acot1 gene by fibrates in the liver. Rats were treated with fenofibrate, bezafibrate, or clofibric acid at various doses for 14 days. The treatments were the same as those described in the legend to Fig. 2, A, # means (clofibric acid-treated) are significantly different from the control (P < 0.05). B: The relationship between the ATGL mRNA level (data from Fig. 4 : A, C, and E) and the Acot1 mRNA level (data from panel A) was determined as y = 0.0434x + 0.4045 (r 2 = 0.9383).
sufficient to substantially reduce hepatic TAG (30) . Therefore, it is likely that mitochondrial b-oxidation, in particular CPT1a, plays a greater role in fatty acid degradation in the liver of fibrate-treated rats, whereas the upregulation of Acox1, a rate-limiting enzyme of peroxisomal b-oxidation, by fibrates plays a physiologically less dominant role in fatty acid catabolism. Collectively, it might be conceivable that upregulation of CPT1a by fibrates may be a cause for reduction of hepatic concentration of TAG by the drugs. However, two facts should be pointed out here. One is the finding of Lankester et al. (31) who suggested that rat hepatocytes preferentially oxidized fatty acid derived from TAG hydrolysis versus those derived from exogenous uptake. The other is that TAG is required to be hydrolyzed to fatty acids before the fatty acids undergo b-oxidation. Until recently, the first step of TAG degradation in the liver was not fully understood. Growing evidence has been emerged indicating that ATGL plays a pivotal role in regulating TAG content in the liver (11 -14) . Recent studies demonstrated that despite ATGL expression in the liver being relatively low compared with those in other tissues, hepatic absence of ATGL causes massive accumulation of TAG in the liver (11 -13) and that the overexpression of ATGL in the liver abolishes hepatic TAG stores (13, 14) . Namely, fatty acids released from TAG by ATGL are channeled to oxidation rather than to other metabolic pathways (14) . Thus, the existing evidence strongly suggest that ATGL dominates the process of reducing hepatic TAG and that fatty acid oxidation by mitochondria and peroxisomes is secondary to TAG hydrolysis by ATGL with regard to TAG catabolism. In this context, among the biochemical manifestations observed in the current study following the administration of fibrates, we consider the importance of the modifications in ATGL caused by fibrates. The present results clearly revealed that the fibrates augmented the expression of ATGL concomitantly with elevation of the gene expression of CGI-58, a cofactor of ATGL (10) . The manifestation was dose-and time-dependent and commonly exhibited by the three fibrates; the order of potency in inducing hepatic ATGL was fenofibrate ≥ bezafibrate > clofibric acid in vivo. Moreover, the present study confirmed that the levels of activity and protein of ATGL were also increased by the treatment of rats with the three fibrates. Importantly, there was a fairly strong inverse correlation between ATGL mRNA level and TAG content in the liver. These results, taken together, lead to the conclusion that ATGL is a key player that triggers TAG degradation by fibrates. On the one hand, it is also more likely that fibrates affected TAG synthesis. There are two sources of fatty acids as substrates for TAG synthesis. One is the fatty acids synthesized de novo in the liver, and the other is the fatty acids taken up from the circulation. The present study confirmed that expression of the FAS gene (de novo fatty acid synthesis) was largely unchanged; accordingly, the supply of de novo synthesis of palmitic acid may not be affected by fibrate treatments. On the other hand, supply of fatty acids from the circulation to hepatocytes is most likely to be increased by fibrates because the expression of the FAT/CD36 gene, a main fatty acid transporter in hepatocytes (32), was strikingly upregulated and that of FATP2 was significantly augmented by fibrates. The current study showed that ACSL3 was significantly upregulated by fibrates. Interestingly, a recent study using lined cells showed that ACSL3 is localized to the endoplasmic reticulum and cytosolic lipid droplets and that ACSL3 not only esterifies fatty acids with CoA but also is involved in the cellular uptake of fatty acids, presumably by indirect metabolic trapping, despite the fact that ACSL3 is not a fatty acid transporter (33) . Therefore, it is likely that ACSL3 upregulated by fibrates activates and channels fatty acids toward the TAG synthesis pathway in the liver. Moreover, in accordance with previous findings (34, 35) , fibrates markedly elevated the expression of both Elovl6 and SCD1 participating in oleic acid synthesis from palmitic acid and stearic acid, results that suggest increased formation of oleic acid not only from palmitic acid synthesized de novo but also from palmitic acid and stearic acid taken up from the circulation. The latter had been demonstrated by our previous study that the in vivo conversion of [ (36, 37) . Therefore, despite slight down-regulation of DGAT2 expression by fibrates, it is most likely that a massive amount of oleic acid is formed and available for the formation of TAG in the liver of rats treated with fibrates because oleic acid is known to be incorporated into TAG more preferentially than other fatty acids (38 -40) . Since a previous study showed that fatty acids released from TAG by ATGL are more readily oxidized than those supplied as fatty acids in media for cultured cells (31) , it is more likely that fatty acids derived from TAG hydrolysis mediated by ATGL underwent boxidation, the activity of which was markedly increased by the treatment with fibrates. As for the secretion of VLDL-TAG, the present study showed that fenofibrate and bezafibrate decreased serum concentration of TAG and that clofibric acid tended to reduce it, but not significantly. These results suggest that the changes in VLDL-TAG secretion into the circulation are not a cause for the fibrate-mediated decrease in hepatic TAG levels.
The ATGL gene is considered to be a PPARa target (41) and fibrates are known to be PPARa agonists (25) , implying the possibility that fibrates induced ATGL in the liver through the activation of PPARa. However, little information is available with respect to potency of fibrates to activate PPARa in the liver in vivo because the potency as a PPARa agonist is generally estimated by a reporter assay employing cultured cells (25) . Since it is difficult to provide definite experimental proof that the induction of ATGL by fibrates working in the liver is quantitatively mediated through the activation of PPARa in vivo, the present study employed an approach to estimate the in vivo potency of the three fibrates by the determination of the increase in mRNA abundance of the Acot1 gene. Acot1 encodes long-chain Acot1 (42, 43) , which was found to be one of two different peroxisome proliferator-inducible palmitoyl-CoA hydrolases in rat liver cytosol and is not a constitutive enzyme in the liver (44) . Moreover, Acot1 has been demonstrated to be regulated by fibrate treatment through the action of PPARa in vivo (43) . The finding may indicate that Acot1 can be used as a likely outcome of activated PPARa working functionally in vivo in the liver. The current results demonstrated a strong correlation between the mRNA levels of Acot1 and ATGL in the liver of rats treated with the three fibrates. This result is not direct proof, but suggests the possible involvement of PPARa activation in ATGL induction by fibrates in the liver.
ATGL overexpression enhances TAG hydrolysis, and the consequential release of fatty acids drives PPARa activity in rat hepatocytes (11, 14, 45) ; conversely, ATGL deficiency leads to down-regulation of PPARa target genes in the liver (11) . These findings strongly suggest that ATGL is critically involved in the hepatocellular mobilization of fatty acids and fatty acid signaling (45) . ATGL resides predominantly on cytosolic lipid droplets and on intracellular membranes (22) . How fatty acids traffic from the lipid droplets to the nucleus to activate PPARa remains unclear, but it is plausible that the process involves FABP (46) . The present study showed that fibrates increased expression of the FABP1 gene, a result that is in good agreement with our previous finding that the treatment of rats with clofibric acid induced FABP protein in the liver (47) . Various types of fatty acids have been shown to activate PPARa (48, 49) . Therefore, it is logical to speculate that fatty acids released from cytosolic lipid droplets by ATGL are channeled to two metabolic pathways. One is that the fatty acids are transported by FABP to mitochondria, where they are exclusively utilized for b-oxidation. The other is that the released fatty acids are similarly transported to the nucleus, where they activate PPARa as its ligand (45) , activation of the transcription factor that relays further stimulation of fatty acid uptake (FAT/CD36), fatty acid trafficking (FABP1), fatty acid activation (ACSL1, 3), mitochondrial b-oxidation (CPT1a, MCAD, LCAD) and peroxisomal b-oxidation (Acox1), and ATGL as well. Thus, ATGL may further expand this positive feedback loop interplaying among PPARa, ATGL, and b-oxidation system in hepatocytes. In doing so, hepatic TAG decreases.
The present study showed that there are differences in the in vivo potency to induce ATGL and to reduce hepatic TAG among fenofibrate, bezafibrate (also referred to as bezafibric acid), and clofibric acid. However, our present study has uncovered strong correlations not only between the hepatic concentrations of fibric acids irrespective of their chemical structures and mRNA levels of ATGL, but also between these and hepatic TAG concentrations. Fibrates, ester forms of fibric acids, are prodrugs, and it is known that they are hydrolyzed by hepatic esterase(s) to form active metabolites, fibric acids. Importantly, the current results suggest that the three fibric acids, fenofibric, bezafibric, and clofibric acids, have almost the same potency to induce ATGL, possibly through activation of PPARa in vivo, in vivo inside the liver. However, it should be noted here that the three fibrates also displayed considerable differences in the mode of action on the expression of genes, which was investigated in the present study (as shown in Table 2 ), despite the fact that intra-hepatic concentrations of fenofibric acid, bezafibric acid, and clofibric acid were largely the same (as shown in Fig. 10A ). These results imply that there is some difference in mode of action among the three fibrates. Finally, the present study evidently revealed that the three fibric acids exhibit ATGL induction and TAG reduction in the liver with largely the same potency. Turpin et al. demonstrated that hepatic ATGL production is reduced in several models of rodent obesity and that ATGL ablation leads to pronounced steatosis, which is characterized by an impairment in fatty acid oxidation, whereas increasing ATGL production in the liver reduces hepatic steatosis and mildly enhances liver insulin sensitivity (13) . Collectively, these findings suggest the possibility that ATGL represents a pharmacological therapeutic target for ameliorating NAFLD and that fibric acids are the likely drugs to ameliorate and/or protect against hepatic steatosis associated with insulin resistance.
